BridgeBio Oncology Therapeutics, Inc. BBOT
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 71.90% | 19.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 30.33% | 6.38% | |||
| Operating Income | -30.33% | -6.38% | |||
| Income Before Tax | -34.08% | -8.53% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -34.08% | -8.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -34.08% | -8.53% | |||
| EBIT | -30.33% | -6.38% | |||
| EBITDA | -30.38% | -6.42% | |||
| EPS Basic | -34.04% | -8.47% | |||
| Normalized Basic EPS | -34.03% | -8.48% | |||
| EPS Diluted | -34.04% | -8.47% | |||
| Normalized Diluted EPS | -34.03% | -8.48% | |||
| Average Basic Shares Outstanding | 0.03% | 0.06% | |||
| Average Diluted Shares Outstanding | 0.03% | 0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||